Methods for bladder cancer therapy using baculoviral vectors

Abstract

There is presently provided methods and uses relating to delivering a nucleic acid molecule to a bladder cell using a baculoviral vector. The bladder cell is contacted with a baculoviral vector, which may further comprise a transgene.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to and benefit of US Provisional Application No. 61 / 622,376, filed April 10, 2012, the contents of which are incorporated herein by reference. technical field [0003] The present invention relates to methods of treating or preventing bladder cancer using baculovirus vectors. Background of the invention [0004] Bladder cancer is the most common form of malignancy in the urethra. In the United States, 69,000 new cases and nearly 15,000 deaths are expected in 2011 (Siegel R et al., 2011). In Singapore, bladder cancer is the 9th most common cancer among men. [0005] Almost all bladder cancers arise from transformed epithelium and are therefore termed transitional cell carcinoma (TCC). Most bladder TCCs are superficial, nonmuscle invasive at initial diagnosis. However, the recurrence rate of superficial TCC after urethrectomy can be as high as 70%, and adjuvant therapy is necessary to...

AI Technical Summary

Problems solved by technology

This reaction prevents further use of the vector or makes subsequent use less effective

Images